Stephen V Liu, MD· @StephenVLiu · X·· 4 天前评分70
正文 · 原文
Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran.
Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
2076 浏览 · 35 赞 · 15 转发 · 0 回复
会议摘要
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683P按 NSCLC, metastatic 对上
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Stephen V Liu, MD · x.com